Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

April 15, 2024

https://www.globenewswire.com/news-release/2024/04/15/2862808/0/en/Caribou-Biosciences-Announces-Oral-Presentation-on-In-Vivo-Cas12a-chRDNA-Genome-Editing-at-the-27th-Annual-Meeting-of-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT.html

BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.